Cbp-0276

Phase 2

CClarent Biopharma, Inc.

Cbp-0276 is one of 2 therapeutic programs targeting Knee. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

KneeRecruiting

KneePhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Knee

#DrugCompanyPhaseTrials

Cbp-0276

CClarent Biopharma, Inc.

Phase 2

1 2

Bone Marrow Aspirate

WWashington University School of Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Knee

NCT07687966

Clinical

Trials by Indication[1]

Knee1 trial

Proof-of-concept, Double-blind, Randomized Clinical Study to Evaluate the Safety and Efficacy of CBP-0276 at Doses of 600 mg/Day vs Placebo in Reducing Opioid Use in Pain Management in Adult Patients Undergoing Major Orthopedic Surgery

Recruiting·CClarent Biopharma, Inc.·Phase 2·NCT07687966·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cbp-0276. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cbp-0276. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Clarent Biopharma, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CClarent Biopharma, Inc.

Cbp-0276

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Knee1 trial

References

Drug Info

Quick Facts

Related News